Summary: A comprehensive study involving over 2.4 million Swedish children has debunked the notion that acetaminophen use during pregnancy increases the risk of autism, ADHD, and intellectual disability in offspring. The research employed a novel sibling comparison method to eliminate confounding familial and environmental factors, revealing no increased risk of neurodevelopmental disorders among siblings exposed to acetaminophen prenatally versus those who were not.
This finding challenges previous reports linking acetaminophen with such risks and offers reassurance to expectant parents regarding the safety of this common pain reliever during pregnancy.
Key Facts:
- No evidence was found linking prenatal acetaminophen exposure to autism, ADHD, or intellectual disability when comparing siblings, one exposed and one not.
- Only 7.5% of the study’s children were exposed to acetaminophen during pregnancy, reflecting cautious use among expectant parents.
- The study suggests that previously observed risks are likely due to other factors, emphasizing the importance of consulting healthcare providers about medication use during pregnancy.
Source: Drexel University
In the largest study to date on the subject, researchers found no evidence to support a causal link between acetaminophen use during pregnancy and increased risk of autism, ADHD and intellectual disability in children.
The findings, using data from a nationwide cohort of over 2.4 million children born in Sweden, including siblings not exposed to the drug before birth, were published today in the Journal of the American Medical Association (JAMA) from researchers at Drexel’s Dornsife School of Public Health and Karolinska Institutet of Sweden.
Advertised as a pain reliever and fever reducer, the generic drug acetaminophen is the active ingredient in Tylenol and is an ingredient in versions of other drugs, such as Theraflu, Excedrin, and Mucinex, among others.
Following each child up to 26 years after birth, the team found a small increased risk of autism, ADHD and intellectual disability in the overall population – as seen in similar previous studies that reported such a link.
However, the authors found no increased risk of any of the conditions when comparing full siblings when one sibling was exposed to acetaminophen while in the uterus before birth and the other sibling was not.
Because siblings share a substantial portion of their genetic background, as well as similar exposure to many of the same environmental factors during development, comparing siblings helps to control for these shared factors that are otherwise hard to measure in epidemiological studies, the authors noted.
“Users of acetaminophen differ from non-users in a number of ways and standard statistical analyses without a sibling control can’t control for all of the differences,” said co-senior author Brian Lee, PhD, an associate professor in Drexel’s Dornsife School of Public Health, fellow at the A.J. Drexel Autism Institute, and research affiliate at the Karolinska Institutet.
“Sibling comparisons allow us to control for familial characteristics that might explain an apparent relationship between acetaminophen use during pregnancy and risk of neurodevelopmental conditions.”
Using data from Sweden’s national health and prescription drug registers, the researchers gathered data on medication use throughout pregnancy for births from 1995 to 2019.
Only about 7.5% of the study sample – 185,909 children – were exposed to acetaminophen during pregnancy. In previous studies, acetaminophen use during pregnancy varied greatly depending on the study setting; a study in Denmark reported 6.2% use while one study in the U.S. reported 10-fold higher use.
Previous studies suggested that many pregnant people, who may benefit from acetaminophen, do not take it for fear of side effects, such as a 2019 study that surveyed 850 pregnant Swedish persons, in which more than 60% considered medication use during early pregnancy to be “probably harmful” or “harmful.”
“This study’s findings may be welcome news for birthing people who use acetaminophen as a pain or fever management option, since there are few safe alternatives for relief available,” said co-senior author Renee M. Gardner, PhD, of Sweden’s Karolinska Institutet.
“We hope that our results provide reassurance to expectant parents when faced with the sometimes fraught decision of whether to take these medications during pregnancy when suffering from pain or fever.”
The authors say all patients should follow the guidance from their physician on whether acetaminophen is safe for them and their future children.
The study authors said that the statistically increased risk of neurodevelopmental disorders in children exposed to acetaminophen in the womb is likely due to other factors.
“Our study and others suggest there are many different health and familial factors that are associated with both acetaminophen use and neurodevelopmental disorders,” said Lee. “Genetics likely play a role, but future work to elucidate this mechanism is crucial.”
In 2015, the U.S. Food and Drug Administration said that studies on over-the-counter pain medicines “are too limited to make any recommendations,” but noted that “severe and persistent pain that is not effectively treated during pregnancy can result in depression, anxiety, and high blood pressure in the mother.”
A 2021 consensus statement in Nature Reviews Endocrinology by an international group of scientists and clinicians recommended that pregnant individuals “minimize exposure (to acetaminophen) by using the lowest effective dose for the shortest possible time” due to research suggesting that prenatal exposure to the drug could increase the risk of neurodevelopmental and other disorders.
Although the Drexel and Karolinska study used data on prescribed acetaminophen and reports from pregnant people to their midwives during prenatal care and may not capture all over-the-counter use in all patients, the findings represent data from a large representative sample and controls for many other factors that may be linked to neurodevelopmental disorders.
Funding: The study was supported by National Institutes of Health’s National Institute of Neurological Disorders and Stroke 1R01NS107607. Beyond funding, NIH had no role in carrying out the study or interpretation of its findings. Lee has received consulting fees for literature reviews for law firms, but has provided no expert litigation, and no external parties had any role in the study.
Other than Gardner and Lee, other authors on the paper include shared lead authors Viktor H. Ahlqvist, PhD, and Hugo Sjöqvist, Christina Dalman, MD, PhD, Håkan Karlsson, PhD, Olof Stephansson, MD, PhD, Stefan Johansson, MD, PhD, and Cecilia Magnusson, MD, PhD, all who hold academic appointments at the Karolinska Institutet.
About this neuropharmacology, ASD, and pregnancy research news
Author: Greg Richter
Source: Drexel University
Contact: Greg Richter – Drexel University
Image: The image is credited to Neuroscience News
Original Research: The findings will appear in JAMA
